Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Official title

Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma

Overview

This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy

Interventions

• Drug GNS561 + Trametinib
  GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg

Primary outcome measures

• Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b) [Time frame: At the end of Cycle 1 (each Cycle is 21 days)]
• Objective response rate (ORR) of the combination of GNS561 with trametinib (Phase 2a) [Time frame: Up to 11 months (estimated)]

Secondary outcome measures (9)

• Duration of response (DoR) [Time frame: Up to 11 months (estimated)]
• Progression-free survival (PFS) [Time frame: Up to 11 months (estimated)]
• Time To Progression (TTP) [Time frame: Up to 11 months (estimated)]
• Disease Control Rate (DCR) [Time frame: Up to 11 months (estimated)]
• Time To Response (TTR) [Time frame: Up to 11 months (estimated)]
• Overall Survival (OS) time [Time frame: Up to approximately 42 months]
• Incidence and severity of treatment emergent adverse event (TEAEs), incidence of serious adverse events (SAEs), incidence of TRAEs, incidence of adverse events of special interest (AESIs), rate of treatment discontinuation or interruption for TRAEs [Time frame: Up to 11 months (estimated)]
• Incidence of clinically significant changes or abnormalities from physical examinations, ophthalmologic assessments, vital signs, performance scores, laboratory results, ECGs, echocardiograms or multigated acquisition scans [Time frame: Up to 11 months (estimated)]
• Drug concentration in plasma for GNS561 and trametinib [Time frame: Predose to Day 21 of Cycle 1 and predose to Day 21 of Cycle 2 (each Cycle is 21 days)]

Eligibility criteria

Inclusion criteria

• Histologically confirmed intrahepatic CCA with a documented KRAS mutation.
• Patients greater than or equal to 18 years of age.
• Patients must have disease progression that is not amenable to potentially curative treatment.
• Patients must have received one or two lines of chemotherapy.
• Patients must have at least one measurable disease by RECIST v1.1.
• Performance status (ECOG) 0-1.
• Adequate organ baseline function defined as follows: absolute neutrophil count ≥1000 cells/μL, platelet count ≥75,000 cells/μL, hemoglobin ≥9 g/dL, aspartate aminotransferase or alanine aminotransferase less than or equal to 3 × upper limit of normal, estimated glomerular filtration rate ≥60 mL/min, corrected QT interval by Fridericia's (QTcF) interval ≤470 msec.
• Women of childbearing potential must present with a negative serum pregnancy test and agree to use adequate contraception during the study and until 6 months after the end of treatment. Male patients with women partners of childbearing potential must agree with the contraception procedures of the study protocol.
• Patients must be able to understand and be willing to comply with the requirements of the study protocol.
• Patients participate voluntarily and sign informed consent form(s).

Exclusion criteria

• Previous treatment with a MEK inhibitor or autophagy inhibitor.
• Previous treatment with three or more lines of prior chemotherapy.
• Extrahepatic CCA with recent (within 6 weeks) placement of a stent or episodes of unstable biliary stents (manifest as obstruction, migration of the stent, infevtion or mechanical failure of the stent) within 6 weeks according to investigator's judgement.
• Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:

• Cardiovascular disorders: congestive heart failure New York Heart Association ≥ class 2 or left ventricular ejection fraction (LVEF) <50%, arrythmias or cardiac conduction abnormalities. Uncontrolled arterial hypertension or inadequately controlled arterial hypertension, at the discretion of the investigator, based on an average of = >3 BP readings over = >2 sessions.
• Patients who have retinal condition (retinal tear, exudate, hemorrhage) or history of retinal vein occlusion or central serous retinopathy or retinal pigment epithelial detachment.
• History of interstitial lung disease or pneumonitis.
• Patients who have clinically significant pleural effusion or ascites.
• Patients who have neurological condition (e.g., tremor, ataxia, hypotension, confusion), history of seizures or active central nervous system metastases.
• Impairment of gastrointestinal function or gastrointestinal disease (e.g., diarrhea, active ulcer disease, history of gastrointestinal perforation/hemorrhage, malabsorption or other conditions that under the judgment of the principal investigator (PI) may impair absorption of study drugs).
• Patients who are taking antineoplastic drugs for concomitant cancer or history of malignancy other than CCA within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%) such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
• Any other condition that would, in the Investigator s judgment, contraindicate the patients' participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection, unable to swallow medication, social/psychological issues, etc).
• Known active viral hepatitis, including HBV and HCV.
• Patients with known allergic reaction to quinoline derivatives (e.g., quinine, chloroquine, mefloquine) and/or hypersensitivity to study drugs.
• Patients who have not recovered for certain AEs due to previous lines of therpay.
• Female patients who are pregnant or lactating at the time of enrollment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 10 centers

• USC Norris Comprehensive Cancer Center — Los Angeles
• LACN Aneheim Flagship Office — Los Angeles
• Orlando Health — Orlando
• Moffitt Cancer Center — Tampa
• University Of Chicago Medical Center — Chicago
• Roswell Park Cancer Institute — Buffalo
• Hospital of the University of Pennsylvania — Philadelphia
• University of Texas, MD Anderson Cancer Center — Houston
• … and 2 more centers

Puerto Rico · 1 center

• Pan American Center for Oncology Trials, LLC — Rio Piedras

Identifiers

NCT: NCT05874414 · GNS561-222-1

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗